Main Session
Sep
28
SS 16 - Early Stage and Locally Advanced NSCLC
180 - Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial
Presenter(s)
Linlin Wang, MD, PhD - Shandong Cancer Hospital and Institute, Jinan, Shandong